MHRA Publishes Strategy 2030: Adaptive Framework Planned for AI Medical Devices and Continued Recognition of CE-Marked Devices

At a Glance

• Publication date: 14 October 2026 — the Medicines and Healthcare products Regulatory Agency (MHRA) issued MHRA Strategy 2030, a 40-page document setting out its regulatory direction for 2026–2030, together with a press release on GOV.UK.
• AI and digital health: an MHRA AI and Digital Health Centre, plus a modern, adaptive regulatory framework for AI as a Medical Device (AIaMD).
• Device data: improved collection and use of medical device data to enable precise identification and traceability across the full device lifecycle.
• Post-market reporting: simpler, faster Yellow Card reporting of adverse events for medicines and devices.
• Market access: broader reliance and recognition routes with trusted regulators, including collaboration with the US FDA and continued recognition of CE-marked devices.
• Enforcement: a substantial increase in criminal enforcement capacity against illegal medicines and medical devices.
• Legal status: a directional strategy, not legislation in force. No specific effective dates for new device rules were given; several commitments require subsequent legislation, public consultation and implementation.

Full Core Content

On 14 October 2026, the MHRA formally published MHRA Strategy 2030 and issued a parallel news release on GOV.UK. The 40-page strategy sets out the agency's regulatory direction for 2026–2030 as a series of public commitments, several of which apply directly to medical devices and digital health products. The article was published on 16 October 2026 under the category Registration and Market Access.

The mission stated at the opening of the strategy is to deliver health and prosperity for all through scientific excellence. The document acknowledges that advances in artificial intelligence, cell and gene therapies, and precision diagnostics are placing pressure on traditional regulatory models and require new approaches to evidence generation, clinical study design, manufacturing oversight and post-market surveillance.

1. Transforming regulation through AI and leading approaches to medical technology

The commitments most relevant to medical device companies fall under the theme of transforming regulation through AI and leading approaches to medical technology. The MHRA states that it will establish an MHRA AI and Digital Health Centre to give developers of digital and AI-driven medical devices and medicinal products clearer regulatory expectations, and that it will build a modern, adaptive regulatory framework for AI as a Medical Device. For companies preparing registrations for software-based or algorithm-based devices, this signals that UK review expectations will be progressively refined over the coming years rather than remaining at the status quo.

2. Device data collection and traceability

A second group of commitments concerns the collection and traceability of device data. The strategy proposes improving the collection and use of medical device data so that devices can be precisely identified and traced throughout their lifecycle, and making it simpler and faster for patients and healthcare professionals to report adverse events relating to medicines and devices through the Yellow Card scheme. Data capability building will directly affect the efficiency of post-market surveillance, field safety corrective actions and recalls.

3. Market access and international collaboration

On market access and international collaboration, the MHRA states that it will expand reliance and recognition pathways with trusted regulatory authorities, including collaboration with the US FDA and continued recognition of CE-marked devices. The strategy also lists other measures intended to improve regulatory efficiency: reducing the expedited scientific advice timeline from 90 days to 45 days; halving the target time for initial assessment of eligible Phase I clinical trials to 14 days; leading the Access Consortium to coordinate market access with Australia, Canada, Singapore and Switzerland; and reducing duplication through regulatory innovation corridor initiatives.

4. Enforcement and compliance

There are also changes in enforcement and compliance. The strategy proposes a substantial increase in criminal enforcement capacity to investigate, disrupt and prosecute activities involving illegal medicines and medical devices, and cooperation with social media platforms and online marketplaces to address misleading information and prevent harmful products from reaching the public. Businesses selling devices through cross-border e-commerce or unauthorised channels should note this commitment.

5. Scope and limits

An important boundary must be stated: this is a directional strategy document, not regulation that has entered into force. The MHRA does not give specific effective dates for new device rules in the document, and a number of commitments must pass through subsequent legislation, public consultation and implementation steps before they take effect. Companies should therefore not treat the strategy as an immediate compliance obligation, but it can be used as an indicator of the direction of UK regulation over the next three to five years.

AIMEILI Regulatory Interpretation

Strategy 2030 should be read as a policy signal rather than an enforceable rulebook. Three elements deserve particular attention from a regulatory affairs perspective.

Adaptive regulation for AI as a Medical Device. The MHRA is positioning itself to move away from a single, static pre-market approval model towards a framework that anticipates iterative algorithm change. For manufacturers of AI-enabled software as a medical device, this implies that future UK requirements are likely to focus on predefined change protocols, performance monitoring, data governance and lifecycle management rather than on a one-off approval decision. The establishment of a dedicated AI and Digital Health Centre also suggests a single, identifiable point of contact and a more predictable review dialogue for digital developers.

Recognition of CE-marked devices. Continued recognition of CE-marked devices preserves a practical market access route into Great Britain for manufacturers who already hold EU certification. In practice, however, the scope and duration of any recognition mechanism depend on the implementing legislation that follows the strategy, so existing CE certification should be maintained and monitored alongside any UK-specific requirements.

Reliance and international convergence. Expanded reliance pathways, including collaboration with the US FDA and coordination through the Access Consortium, point towards greater weight being given to decisions and inspections performed by comparable authorities. This reduces duplication for global registration programmes, but it also raises the bar on the quality of source documentation, since reliance assumes that the originating assessment is complete and defensible.

Traceability and enforcement. Enhanced device identification and traceability, easier adverse event reporting and stronger criminal enforcement collectively shift regulatory attention towards the post-market phase. UDI-level data quality, complaint handling, field safety corrective action readiness and control over distribution channels become more consequential than the initial registration alone.

Business Impact

• Manufacturers holding CE certification: a continued recognition route supports continuity of UK market access, but legal certainty depends on the enabling legislation to follow. Maintain EU certificates and monitor UK implementing measures in parallel.
• AI and software device developers: plan for a more explicit UK evidence package covering algorithm change control, clinical performance, dataset provenance and ongoing monitoring; early engagement with the MHRA AI and Digital Health Centre will become a practical advantage.
• Clinical trial sponsors and CROs: a 14-day target for initial assessment of eligible Phase I trials and a 45-day expedited scientific advice pathway can shorten UK start-up and advice timelines; supporting documentation should be prepared to a standard that can sustain the accelerated review.
• Global registration programmes: increasing reliance on trusted authority decisions, including FDA assessments, favours a coordinated dossier strategy in which one high-quality core assessment supports multiple markets.
• Distributors and e-commerce sellers: heightened criminal enforcement and cooperation with online marketplaces increase the risk exposure of unauthorised or cross-border channels; supply chain authorisation and product traceability should be reviewed.
• Post-market functions: investment in device identification, complaint data and recall readiness is likely to yield direct regulatory benefit as traceability and reporting expectations tighten.
• Planning horizon: because the strategy is directional, allocate resources to monitoring and gap analysis now, rather than to immediate remediation against requirements that are not yet in force.

Sources and Verification

• UK Government (GOV.UK) — MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines (news release, published 14 October 2026): https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines
• UK Government (GOV.UK) — MHRA Strategy 2030 (full strategy and executive summary, published 14 October 2026): https://www.gov.uk/government/publications/mhra-strategy-2030
• UK Government (GOV.UK) — MHRA Strategy to 2030: What it means for you (thematic explainer page): https://www.gov.uk/government/publications/mhra-strategy-to-2030-what-it-means-for-you
• Verification scope and access date: the GOV.UK news release page, the MHRA Strategy 2030 publication page and the MHRA agency updates page were reviewed on 16 October 2026 (Asia/Shanghai).

Applicability note: this article is an interpretation of a public MHRA strategy document and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The official source texts prevail, and the commitments described may change as subsequent legislation, consultations and official updates are issued.